Literature DB >> 12605682

High activity of human butyrylcholinesterase at low pH in the presence of excess butyrylthiocholine.

Patrick Masson1, Florian Nachon, Cynthia F Bartels, Marie-Therese Froment, Fabien Ribes, Cedric Matthews, Oksana Lockridge.   

Abstract

Butyrylcholinesterase is a serine esterase, closely related to acetylcholinesterase. Both enzymes employ a catalytic triad mechanism for catalysis, similar to that used by serine proteases such as alpha-chymotrypsin. Enzymes of this type are generally considered to be inactive at pH values below 5, because the histidine member of the catalytic triad becomes protonated. We have found that butyrylcholinesterase retains activity at pH <or= 5, under conditions of excess substrate activation. This low-pH activity appears with wild-type butyrylcholinesterase as well as with all mutants we examined: A328G, A328I, A328F, A328Y, A328W, E197Q, L286W, V288W and Y332A (residue A328 is at the bottom of the active-site gorge, near the pi-cation-binding site; E197 is next to the active-site serine S198; L286 and V288 form the acyl-binding pocket; and Y332 is a component of the peripheral anionic site). For example, the kcat value at pH 5.0 for activity in the presence of excess substrate was 32900 +/- 4400 min(-1) for wild-type, 55200 +/- 1600 min(-1) for A328F, and 28 700 +/- 700 min(-1) for A328W. This activity is titratable, with pKa values of 6.0-6.6, suggesting that the catalytic histidine is protonated at pH 5. The existence of activity when the catalytic histidine is protonated indicates that the catalytic-triad mechanism of butyrylcholinesterase does not operate for catalysis at low pH. The mechanism explaining the catalytic behaviour of butyrylcholinesterase at low pH in the presence of excess substrate remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605682     DOI: 10.1046/j.1432-1033.2003.03388.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  An evaluation of the inhibition of human butyrylcholinesterase and acetylcholinesterase by the organophosphate chlorpyrifos oxon.

Authors:  Josephine Shenouda; Paula Green; Lester Sultatos
Journal:  Toxicol Appl Pharmacol       Date:  2009-08-19       Impact factor: 4.219

2.  Plants as a source of butyrylcholinesterase variants designed for enhanced cocaine hydrolase activity.

Authors:  Katherine E Larrimore; Matthew Barcus; Latha Kannan; Yang Gao; Chang-Guo Zhan; Stephen Brimijoin; Tsafrir Mor
Journal:  Chem Biol Interact       Date:  2012-09-20       Impact factor: 5.192

3.  Purification, characterization, and N-glycosylation of recombinant butyrylcholinesterase from transgenic rice cell suspension cultures.

Authors:  Jasmine M Corbin; Muchena J Kailemia; C Linn Cadieux; Salem Alkanaimsh; Kalimuthu Karuppanan; Raymond L Rodriguez; Carlito B Lebrilla; Douglas M Cerasoli; Karen A McDonald; Somen Nandi
Journal:  Biotechnol Bioeng       Date:  2018-02-27       Impact factor: 4.530

4.  ENZO: a web tool for derivation and evaluation of kinetic models of enzyme catalyzed reactions.

Authors:  Staš Bevc; Janez Konc; Jure Stojan; Milan Hodošček; Matej Penca; Matej Praprotnik; Dušanka Janežič
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

5.  First evidence of cholinesterase-like activity in Basidiomycota.

Authors:  Kristina Sepčić; Jerica Sabotič; Robin A Ohm; Damjana Drobne; Anita Jemec Kokalj
Journal:  PLoS One       Date:  2019-04-30       Impact factor: 3.240

6.  Transient Expression of Tetrameric Recombinant Human Butyrylcholinesterase in Nicotiana benthamiana.

Authors:  Salem Alkanaimsh; Kalimuthu Karuppanan; Andrés Guerrero; Aye M Tu; Bryce Hashimoto; Min Sook Hwang; My L Phu; Lucas Arzola; Carlito B Lebrilla; Abhaya M Dandekar; Bryce W Falk; Somen Nandi; Raymond L Rodriguez; Karen A McDonald
Journal:  Front Plant Sci       Date:  2016-06-16       Impact factor: 5.753

7.  Phenoxyethyl Piperidine/Morpholine Derivatives as PAS and CAS Inhibitors of Cholinesterases: Insights for Future Drug Design.

Authors:  Yaghoub Pourshojaei; Ardavan Abiri; Khalil Eskandari; Zahra Haghighijoo; Najmeh Edraki; Ali Asadipour
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.